

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
CytImmune Sciences, Inc.	09/17/2009

RECEIVING PARTY DATA

Name:	Hidetaka Kentaro Itani
Street Address:	1737 Holly Lane
City:	Pittsburgh
State/Country:	PENNSYLVANIA
Postal Code:	15216

PROPERTY NUMBERS Total: 37

Property Type	Number
Application Number:	60287363
Application Number:	10325485
Application Number:	10672144
Application Number:	60526360
Application Number:	60540075
Application Number:	11004623
Application Number:	11046204
Application Number:	11805383
Application Number:	11516175
Application Number:	60974310
Application Number:	60981920
Application Number:	11923344
Application Number:	60986494
Application Number:	61069108
Application Number:	61069905

CH \$1480.00 60287363

500966748

**PATENT
 REEL: 023254 FRAME: 0076**

Application Number:	61040022
Application Number:	61123796
Application Number:	61124079
Application Number:	61124290
Application Number:	61126899
Application Number:	12235342
Application Number:	12250126
Application Number:	12267847
Application Number:	12373135
Application Number:	61228243
PCT Number:	US9403177
PCT Number:	US0213753
PCT Number:	US0503454
PCT Number:	US0440785
PCT Number:	US0882984
PCT Number:	US0877239
PCT Number:	US0882956
Patent Number:	6274552
Patent Number:	6407218
Patent Number:	6528051
Patent Number:	7229841
Patent Number:	7387900

CORRESPONDENCE DATA

Fax Number: (312)609-5005
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 312-609-7897
Email: hmiller@vedderprice.com
Correspondent Name: Holly Miller
Address Line 1: 222 North LaSalle Street - 24th Floor
Address Line 4: Chicago, ILLINOIS 60601

ATTORNEY DOCKET NUMBER:	38919.00.0002/HMM/GIGI M.
NAME OF SUBMITTER:	Holly Miller

Total Attachments: 10
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page1.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page2.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page3.tif

source=Patent Security Agreement from CytImmune to Hidetaka Itani#page4.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page5.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page6.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page7.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page8.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page9.tif
source=Patent Security Agreement from CytImmune to Hidetaka Itani#page10.tif

PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT (this "Agreement") made as of this 17th day of September, 2009 by CytImmune Sciences, Inc., a Delaware corporation, located at 9640 Medical Center Drive, Rockville, Maryland 20850 ("Grantor"), in favor of Hidetaka Kentaro Itani, an individual, located at 1737 Holly Lane, Pittsburg, Pennsylvania, 15216 ("Grantee").

W I T N E S S E T H:

WHEREAS, Grantor and Grantee are parties to that certain Amended and Restated Bridge Loan Agreement dated as of even date herewith (as the same may be further amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement") providing for the extensions of credit to be made to Grantor by Grantee;

WHEREAS, as a condition precedent to the availability of such loan and other financial accommodations under the Loan Agreement, Grantor has executed and delivered that certain Security Agreement, dated as of even date herewith (the "Security Agreement"), between Grantor and Grantee, pursuant to which Grantor has granted to Grantee a security interest in substantially all of the assets of Grantor including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired patents, patent registrations and patent applications and all renewals, extensions and continuations of any of the foregoing (the "Patents"), and all products and proceeds thereof, to secure the payment of all amounts owing by Grantor under the Loan Agreement; and

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Loan Agreement and Security Agreement. The Loan Agreement and Security Agreement and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto. All terms capitalized but not otherwise defined herein shall have the same meanings herein as in the Security Agreement.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations, Grantor hereby grants to Grantee a continuing security interest in Grantor's entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the "Patent Collateral"), whether now owned or existing or hereafter created, acquired or arising:

- (i) each Patent and application for Patent listed on Schedule 1 annexed hereto, together with any reissues, continuations or extensions thereof; and
- (ii) all products and proceeds of the foregoing, including, without limitation, any claim by Grantor against third parties for past, present or future infringement of any Patent.

[SIGNATURE PAGE FOLLOWS]


(Signature Page to Patent Security Agreement)

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

GRANTOR:

CYTIMMUNE SCIENCES, INC., a Delaware corporation

By:

A handwritten signature in black ink, appearing to read "Lawrence Tamarkin", written over a horizontal line.


Name: Lawrence Tamarkin, Ph.D.

Title: President and Chief Executive Officer

(Signature Page to Patent Security Agreement)

Agreed and Accepted
As of the Date First Written Above

GRANTEE:


Hidetaka Kentaro Itani, an individual

SCHEDULE 1

PATENTS (U.S.)

<u>Patent Description</u>	<u>U.S. Patent No.</u>
Composition and method for delivery of biologically-active factors	6,274,552
Human monoclonal antibodies and in vitro method for their production	6,407,218
Methods and compositions for enhancing immune response and for the production of in vitro MABs	6,528,051
Colloidal metal compositions and methods	7,229,841
Colloidal metal compositions and methods	7,387,900

PATENT APPLICATIONS (U.S.)

<u>Patent Description</u>	<u>U.S. Patent No.</u>	<u>Filing Date</u>
Colloidal metal compositions and methods	60/287,363	04/30/2001
Methods and compositions for enhancing immune response and for the production of in vitro MABs	10/325,485	12/19/2002
Compositions and methods for targeted delivery of factors	10/672,144	09/26/2003
Methods and compositions for the production of monoclonal antibodies	60/526,360	12/02/2003
Functionalized colloidal metal compositions and methods	60/540,075	01/28/2004
Methods and composition for the production of monoclonal antibodies	11/004,623	12/02/2004
Functionalized colloidal metal compositions and methods	11/046,204	01/28/2005
Colloidal metal compositions and methods	11/805,383	05/22/2007
Colloidal metal compositions and methods	11/516,175	09/06/2006

<u>Patent Description</u>	<u>U.S. Patent No.</u>	<u>Filing Date</u>
Colloidal metal compositions and methods	60/974,310	09/21/2007
Colloidal metal compositions and methods	60/981,920	10/23/2007
Colloidal metal compositions and methods	11/923,344	10/24/2007
Compositions and methods for generating antibodies	60/986,494	11/08/2007
Colloidal metal compositions and methods (HES)	61/069,108	03/12/2008
Colloidal metal compositions and methods (PolyPEGS)	61/069,905	03/19/2008
Colloidal metal compositions and methods (rPEGs)	61/040,022	03/27/2008
Colloidal metal compositions and methods (CYT-6091)	61/123,796	04/11/2008
Compositions and methods for generating antibodies	61/124,079	04/11/2008
Colloidal metal compositions and methods (CYT-20000)	61/124,290	04/15/2008
Colloidal metal compositions and methods	61/126,899	05/08/2008
Nanotherapeutic colloidal metal compositions and methods	12/235,342	09/22/2008
Compositions and methods for targeted delivery of factors	12/250,126	10/13/2008
Compositions and methods for generating antibodies	12/267,847	11/10/2008
Thiolated paclitaxels and gold nanoparticles as drug delivery agents ¹	12/373,135	11/10/2008
Colloidal gold nanoparticles	61/228,243	07/24/2009

¹ Jointly owned with Virginia Tech Intellectual Properties, Inc.

PATENTS (FOREIGN)

Austria

<u>Patent Description</u>	<u>Patent No.</u>
Composition and method for reducing toxicity of biologically-active factors	E 270 111
Composition and method for targeted delivery of factors	E 320 270
Methods and compositions for enhancing immune response and for the production of in vitro MABs	E 317 269

Australia

<u>Patent Description</u>	<u>Patent No.</u>
Composition and methods for targeted delivery of factors	760035
Composition and methods for targeted delivery of factors	2003231660
Methods and compositions for enhancing immune response and for the production of in vitro MABs	757,357
Methods and compositions for enhancing immune response and for the production of in vitro MABs	2003204353
Colloidal metal compositions and methods	2002259107
Colloidal metal compositions and methods	2007200363

Canada

<u>Patent Description</u>	<u>Patent No.</u>
Composition and method for reducing toxicity of biologically-active factors	2,158,475

EPO

<u>Patent Description</u>	<u>Patent No.</u>
Composition and method for reducing toxicity of biologically-active factors	0690722
Compositions and methods for targeted delivery of factors	1044022
Methods and compositions for enhancing immune response and for the production of in vitro MABs	1039933

France

<u>Patent Description</u>	<u>Patent No.</u>
Composition and method for reducing toxicity of biologically-active factors	0690722
Compositions and methods for targeted delivery of factors	1044022

Methods and compositions for enhancing immune response and for the production of in vitro MABs

1039933

Germany

Patent Description	Patent No.
Composition and method for reducing toxicity of biologically-active factors	69433870.2-08
Compositions and methods for targeted delivery of factors	69833876.6
Methods and compositions for enhancing immune response and for the production of in vitro MABs	69833455.8

Ireland

Patent Description	Patent No.
Compositions and methods for targeted delivery of factors	1044022
Methods and compositions for enhancing immune response and for the production of in vitro MABs	1039933

Italy

Patent Description	Patent No.
Composition and method for reducing toxicity of biologically-active factors	0690722
Compositions and methods for targeted delivery of factors	1044022
Methods and compositions for enhancing immune response and for the production of in vitro MABs	1039933

Japan

Patent Description	Patent No.
Composition and method for reducing toxicity of biologically-active factors	3880063

New Zealand

Patent Description	Patent No.
Compositions and methods for targeted delivery of factors	504291
Methods and compositions for enhancing immune response and for the production of in vitro MABs	504292

United Kingdom

Patent Description	Patent No.
Composition and method for reducing toxicity of	0690722

biologically-active factors

Compositions and methods for targeted delivery of factors 1044022

Methods and compositions for enhancing immune response and for the production of in vitro MABs 1039933

PATENT APPLICATIONS (FOREIGN)

Australia

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Methods and compositions for enhancing immune response and for the production of in vitro MABs	2006235956	11/10/2006
Functionalized colloidal metal compositions and methods	2005209318	01/28/2005
Methods and compositions for the production of monoclonal antibodies	2004311630	12/02/2004

Canada

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Composition and methods for targeted delivery of factors	2,309,604	11/10/1998
Methods and compositions for enhancing immune response and for the production of in vitro MABs	2,309,602	11/10/1998
Colloidal metal compositions and methods	2,448,607	04/30/2002
Functionalized colloidal metal compositions and methods	2,554,755	01/28/2005
Methods and compositions for the production of monoclonal antibodies	2,548,179	12/02/2004

China

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Functionalized colloidal metal compositions and methods	200580009719.0	01/28/2005
Methods and compositions for the production of monoclonal antibodies	200480041234.5	12/02/2004

EPO

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Colloidal metal compositions and methods	02729092.3	04/30/2002
Functionalized colloidal metal compositions and methods	05722715.9	01/28/2005
Methods and compositions for the production of monoclonal antibodies	04821049.6	12/02/2004

Hong Kong

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Functionalized colloidal metal compositions and methods	07104685.5	05/02/2007
Methods and compositions for the production of monoclonal antibodies	07101689.7	02/13/2007

India

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Functionalized colloidal metal compositions and methods	2225/KOL NP/06	01/28/2005

Israel

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Covalently pegylated colloidal gold compositions	158654	04/03/2002
Colloidal metal compositions and methods	184282	04/30/2002
Functionalized colloidal metal compositions and methods	177075	01/28/2005
Methods and compositions for the production of monoclonal antibodies	175985	02/12/2004

Japan

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Compositions and methods for targeted delivery of factors	2000-520162	11/10/1998
Methods and compositions for enhancing immune response and for the production of in vitro MABs	2000-520153	11/10/1998

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Methods and compositions for enhancing immune response and for the production of in vitro MABs	2009-144707	06/17/2009
Colloidal metal compositions and methods	2002-584861	04/30/2002
Colloidal metal compositions and methods	2009-156423	04/30/2002
Functionalized colloidal metal compositions and methods	2006-551620	01/28/2005
Methods and compositions for the production of monoclonal antibodies	2006-544857	12/02/2004

PCT

<u>Patent Description</u>	<u>Patent No.</u>	<u>Filing Date</u>
Composition and method for reducing toxicity of biologically-active factors	PCT/US94/003177	03/18/1994
Colloidal metal compositions and methods	PCT/US02/013753	04/30/2002
Functionalized colloidal metal compositions and methods	PCT/US05/003454	01/28/2005
Methods and compositions for the production of monoclonal antibodies	PCT/US04/040785	12/02/2004
Compositions and methods for generating antibodies	PCT/US2008/082984	11/10/2008
Nanotherapeutic colloidal metal compositions and methods	PCT/US2008/077239	09/22/2008
Thiolated paclitaxels and gold nanoparticles as drug delivery agents ²	PCT/US2008/082956	11/10/2008

² Jointly owned with Virginia Tech Intellectual Properties, Inc.